Tyrosine kinase inhibitors

Current Cancer Drug Targets

Volumn 10, Issue 5, 2010, Pages 462-483

  Natoli, C ^a   Perrucci, B ^a   Perrotti, F ^a   Falchi, L ^b   Iacobelli, S ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Angiogenesis; HER family; Multitarget; Nonreceptors; Receptors; Resistance; Tyrosine kinase Inhibitors

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ALPHA INTERFERON; ALPHA2A INTERFERON; AXITINIB; BCR ABL PROTEIN; CANERTINIB; CAPECITABINE; CD 1033; CEDIRANIB; CISPLATIN; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NILOTINIB; OXALIPLATIN; PAZOPANIB; PELITINIB; PEMETREXED; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; APOPTOSIS; APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GLIOBLASTOMA; GLIOMA; GYNECOLOGIC CANCER; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA; OVARY CANCER; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RASH; RECOMMENDED DRUG DOSE; SARCOMA; SIDE EFFECT; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; DRUG ANTAGONISM; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 77956534350     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791517208     Document Type: Article

References (306)

1. Robinson, D. R.; Wu, Y. M.; Lin, S. F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19, 5548-5557.
2. Shawver, L. K.; Slamon, D.; Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1, 117-123.
3. Heldin, C. H. Dimerization of cell surface receptors in signal transduction, Cell 1995, 80, 213-223.
4. Hubbard, S. R.; Mohammadi, M.; Schlessinger, J. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 1998, 273, 11987-11990.
5. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
6. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411, 355-365.
7. Ullrich, A.; Coussens, L.; Hayflick, J. S.; Dull, T. J.; Gray, A.; Tam, A. W.; Lee, J.; Yarden, Y.; Libermann, T. A.; Schlessinger, J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309, 418-425.
8. Coussens, L.; Yang-Feng, T. L.; Liao, Y. C.; Chen, E.; Gray, A.; McGrath, J.; Seeburg, P. H.; Libermann, T. A.; Schlessinger, J.; Francke, U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230, 1132-1139.
9. Kraus, M. H.; Issing, W.; Miki, T.; Popescu, N. C.; Aaronson, S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA 1989, 86, 9193-9197.
10. Plowman, G. D.; Culouscou, J. M.; Whitney, G. S.; Green, J. M; Carlton, G. W.; Foy, L.; Neubauer, M. G.; Shoyab, M. Ligandspecific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA 1993, 90, 1746-1750.
11. Guy, P. M.; Platko, J. V.; Cantley, L. C.; Cerione, R. A.; Carraway, K. L. 3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 1994, 91, 8132-8136.
12. Klapper, L. N.; Glathe, S.; Vaisman, N.; Hynes, N. E.; Andrews, G. C.; Sela, M.; Yarden, Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA 1999, 96, 4995-5000.
13. Normanno, N.; Bianco, C.; De Luca, A.; Maiello, M. R.; Salomon, D. S. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 2003, 10, 1-21.
14. Graus-Porta, D.; Beerli, R. R.; Daly, J. M.; Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling. EMBO J. 1997, 16, 1647-1655.
15. Roskoski, R. Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 2004, 319, 1-11.
16. Karunagaran, D.; Tzahar, E.; Beerli, R. R.; Chen, X.; Graus-Porta, D.; Ratzkin, B. J.; Seger, R.; Hynes, N. E.; Yarden, Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J. 1996, 15, 254-264.
17. Scholl, S.; Beuzeboc, P.; Pouillart, P. Targeting HER2 in other tumor types. Ann. Oncol. 2001, 12, S81-87.
18. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER 2/neu oncogene. Science 1987, 235, 177-182.
19. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
20. Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 2001, 11, 1911-1914.
21. Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; Di Orio, C.; Doty, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57, 4838-4848.
22. Rusnak, D. W.; Affleck, K.; Cockerill, S. G.; Stubberfield, C.; Harris, R.; Page, M.; Smith, K. J.; Guntrip, S. B.; Carter, M. C.; Shaw, R. J.; Jowett, A.; Stables, J.; Topley, P.; Wood, E. R.; Brignola, P. S.; Kadwell, S. H.; Reep, B. R.; Mullin, R. J.; Alligood, K. J.; Keith, B. R.; Crosby, R. M.; Murray, D. M.; Knight, W. B.; Gilmer, T. M.; Lackey, K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001, 61, 7196-7203.
23. Salomon, D. S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232.
24. Yoon, S.; Seger, R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24, 21-44.
25. Friday, B. B.; Adjei, A. A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 2008, 14, 342-346.
26. Karnoub, A. E.; Weinberg, R. A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9, 517-531.
27. Henson, E. S.; Gibson, S. B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal. 2006, 18, 2089-2097.
28. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer Statistics, 2008. CA Cancer J. Clin. 2009, 59, 225-249.
29. Wheatley-Price, P.; Shepherd, F. A. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr. Opin. Oncol. 2008, 20, 162-175.
30. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
31. Ciardiello, F.; Caputo, R.; Troiani, T.; Borriello, G.; Kandimalla, E. R.; Agrawal, S.; Mendelsohn, J.; Bianco, A. R.; Tortora, G. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int. J. Cancer 2001, 93, 172-178.
32. Helfrich, B. A.; Raben, D.; Varella-Garcia, M.; Gustafson, D.; Chan, D. C.; Bemis, L.; Coldren, C.; Barón, A.; Zeng, C.; Franklin, W. A.; Hirsch, F. R.; Gazdar, A.; Minna, J.; Bunn, P. A. Jr. Tumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin. Cancer Res. 2006, 12, 7117-7125.
33. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL Trial). J. Clin. Oncol. 2003, 21, 2237-2246.
34. Shepherd, F. A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353, 123-132.
35. Uramoto, H.; Mitsudomi, T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br. J. Cancer 2007, 96, 857-863.
36. Greulich, H.; Chen, T. H.; Feng, W.; Jänne, P. A.; Alvarez, J. V.; Zappaterra, M.; Bulmer, S. E.; Frank, D. A.; Hahn, W. C.; Sellers, W. R.; Meyerson, M. Oncogenic transformation by inhibitorsensitive and -resistant EGFR mutants. PLoS Med. 2005, 2, e313.
37. Kumar, A.; Petri, E. T.; Halmos, B.; Boggon, T. J. Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. J. Clin. Oncol. 2008, 26, 1742-1751.
38. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163-1167.
39. Tamura, K.; Okamoto, I.; Kashii, T.; Negoro, S.; Hirashima, T.; Kudoh, S.; Ichinose, Y.; Ebi, N.; Shibata, K.; Nishimura, T.; Katakami, N.; Sawa, T.; Shimizu, E.; Fukuoka, J.; Satoh, T.; Fukuoka, M.; West Japan Thoracic Oncology Group. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer 2008, 98, 907-914.
40. Takano, T.; Ohe, Y.; Sakamoto, H.; Tsuta, K.; Matsuno, Y.; Tateishi, U.; Yamamoto, S.; Nokihara, H.; Yamamoto, N.; Sekine, I.; Kunitoh, H.; Shibata, T.; Sakiyama, T.; Yoshida, T.; Tamura, T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 6829-6837.
41. Tsao, M. S.; Sakurada, A.; Cutz, J. C.; Zhu, C. Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F. A. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353, 133-144.
42. Cappuzzo, F.; Varella-Garcia, M.; Shigematsu, H.; Domenichini, I.; Bartolini, S.; Ceresoli, G. L.; Rossi, E.; Ludovini, V.; Gregorc, V.; Toschi, L.; Franklin, W. A.; Crino, L.; Gazdar, A. F.; Bunn, P. A. Jr.; Hirsch, F. R. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 2005, 23, 5007-5018.
43. Sasaki, H.; Endo, K.; Takada, M.; Kawahara, M.; Kitahara, N.; Tanaka, H.; Okumura, M.; Matsumur,a A.; Iuchi, K.; Kawaguchi, T.; Kawano, O.; Yukiue, H.; Yokoyama, T.; Yano, M.; Fujii, Y. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007, 58, 324-328.
44. Pao, W.; Wang, T. Y.; Riely, G. J.; Miller, V. A.; Pan, Q.; Ladanyi, M.; Zakowski, M. F.; Heelan, R. T.; Kris, M. G.; Varmus, H. E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2, e17.
45. Gandhi, J.; Zhang, J.; Xie, Y.; Soh, J.; Shigematsu, H.; Zhang, W.; Yamamoto, H.; Peyton, M.; Girard, L.; Lockwood, W. W.; Lam, W. L.; Varella-Garcia, M.; Minna, J. D.; Gazdar, A. F. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009, 4, e4576.
46. Onitsuka, T.; Uramoto, H.; Nose, N.; Takenoyama, M.; Hanagiri, T.; Sugio, K.; Yasumoto, K. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010, 68, 198-203.
47. Yamada, T.; Matsumoto, K.; Wang, W.; Li, Q.; Nishioka, Y.; Sekido, Y.; Sone, S.; Yano, S. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin. Cancer Res. 2010, 16, 174-183.
48. Gazdar, A. F. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010, 29, 37-48.
49. Cohen, M. H.; Williams, G. A.; Sridhara, R.; Chen, G.; McGuinn, W. D. Jr.; Morse, D.; Abraham, S.; Rahman, A.; Liang, C.; Lostritto, R.; Baird, A.; Pazdur, R. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8, 303-306.
50. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues, Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E. H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366, 1527-1537.
51. Kim, E. S.; Hirsh, V.; Mok, T.; Socinski, M. A.; Gervais, R.; Wu, Y. L.; Li, L. Y.; Watkins, C. L.; Sellers, M. V.; Lowe, E. S.; Sun, Y.; Liao, M. L.; Osterlind, K.; Reck, M.; Armour, A. A.; Shepherd, F.A.; Lippman, S. M.; Douillard, J. Y. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372, 1809-1818.
52. Douillard, J. Y.; Shepherd, F. A.; Hirsh, V.; Mok, T.; Socinski, M. A.; Gervais, R.; Liao, M. L.; Bischoff, H.; Reck, M.; Sellers, M. V.; Watkins, C. L.; Speake, G.; Armour, A. A.; Kim, E. S. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J. Clin. Oncol. 2010, 28, 744-752.
53. Yun, C. H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007, 11, 217-227.
54. Higgins, B.; Kolinsky, K.; Smith, M.; Beck, G.; Rashed, M.; Adames, V.; Linn, M.; Wheeldon, E.; Gand, L.; Birnboeck, H.; Hoffmann, G. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004, 15, 503-512.
55. Frohna, P.; Lu, J.; Eppler, S.; Hamilton, M.; Wolf, J.; Rakhit, A.; Ling, J.; Kenkare-Mitra, S. R.; Lum, B. L. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J. Clin. Pharmacol. 2006, 43, 282-290.
56. Hidalgo, M.; Siu, L. L.; Nemunaitis, J.; Rizzo, J.; Hammond, L. A.; Takimoto, C.; Eckhardt, S. G.; Tolcher, A.; Britten, C. D.; Denis, L.; Ferrant, K.; Von Hoff, D. D.; Silberman, S.; Rowinsky, E. K. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 2001, 19, 3267-3279.
57. Tran, H. T.; Zinner, R. G.; Blumenschein, G. R. Jr.; Oh, Y. W.; Papadimitrakopoulou, V. A.; Kim, E. S.; Lu, C.; Malik, M.; Lum, B. L.; Herbst, R. S. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest. New Drugs 2010, Jan 22.[Epub ahead of print].
58. Li, J.; Cusatis, G.; Brahmer, J.; Sparreboom, A.; Robey, R. W.; Bates, S. E.; Hidalgo, M.; Baker, S. D. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther. 2007, 6, 432-438.
59. Engelman, J. A.; Janne, P. A. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer. Clin. Cancer Res. 2008, 14, 2895-2899.
60. Cho, B. C.; Im, C. K.; Park, M. S.; Kim, S. K.; Chang, J.; Park, J. P.; Choi, H. J.; Kim, Y. J.; Shin, S. J.; Sohn, J. H. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J. Clin. Oncol. 2007, 25, 2528-2533.
61. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Jänne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792.
62. Balak, M. N.; Gong, Y.; Riely, G. J.; Somwar, R.; Li, A. R.; Zakowski, M. F.; Chiang, A.; Yang, G.; Ouerfelli, O.; Kris, M. G.; Ladanyi, M.; Miller, V. A.; Pao, W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 2006, 12, 6494-6501.
63. Kosaka, T.; Yatabe, Y.; Endoh, H.; Yoshida, K.; Hida, T.; Tsuboi, M.; Tada, H.; Kuwano, H.; Mitsudomi, T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 2006, 12, 5764-5769.
64. Toschi, L.; Cappuzzo, F. Clinical implications of MET gene copy number in lung cancer. Future Oncol. 2010, 6, 239-247.
65. Eberhard, D. A.; Johnson, B. E.; Amler, L. C.; Goddard, A. D.; Heldens, S. L.; Herbst, R. S.; Ince, W. L.; Janne, P. A.; Januario, T.; Johnson, D. H. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 2005, 23, 5900-5909.
66. Linardou, H.; Dahabreh, I. J.; Kanaloupiti, D.; Siannis, F.; Bafaloukos, D.; Kosmidis, P.; Papadimitriou, C. A.; Murray, S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9, 962-972.
67. Xia, W.; Husain, I.; Liu, L.; Bacus, S.; Saini, S.; Spohn, J.; Pry, K.; Westlund, R.; Stein S. H.; Spector, N. L. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007, 67, 1170-1175.
68. Suzuki, Y.; Orita, M.; Shiraishi, M.; Hayashi, K.; Sekiya, T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990, 5, 1037-1043.
69. Malumbres, M.; Barbacid, M. RAS oncogenes: The first 30 years. Nat. Rev. Cancer 2003, 3, 459-465.
70. Suda, K.; Tomizawa, K.; Mitsudomi, T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010, 29, 49-60.
71. Brose, M. S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62, 6997-7000.
72. Di Nicolantonio, F.; Martini, M.; Molinari, F.; Sartore-Bianchi, A.; Arena, S.; Saletti, P.; De Dosso, S.; Mazzucchelli, L.; Frattini, M.; Siena, S.; Bardelli, A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26, 5705-5712.
73. Sartore-Bianchi, A.; Martini, M.; Molinari, F.; Veronese, S.; Nichelatti, M.; Artale, S.; Di Nicolantonio, F.; Saletti, P.; De Dosso, S.; Mazzucchelli, L.; Frattini, M.; Siena, S.; Bardelli, A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009, 69, 1851-1857.
74. Herbst, R. S.; Giaccone, G.; Schiller, J. H.; Natale, R. B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell R.; Oliff, I.; Reeves J. A.; Wolf, M. K.; Krebs, A. D.; Averbuch, S. D.; Ochs, J. S.; Grous, J.; Fandi, A.; Johnson, D. H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 2004, 22, 785-794.
75. Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F.; Milanowski, J.; Karnicka-Mlodkowski, H.; Pesek, M.; Serwatowski, P.; Ramlau, R.; Janaskova, T.; Vansteenkiste, J.; Strausz J.; Manikhas, G. M.; Von Pawel, J. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 2007, 25, 1545-1552.
76. Azzoli, C. G.; Baker, S. Jr.; Temin, S.; Pao, W.; Aliff, T.; Brahmer, J.; Johnson, D. H.; Laskin, J. L.; Masters, G.; Milton, D.; Nordquist, L.; Pfister, D. G.; Piantadosi, S.; Schiller, J. H.; Smith, R.; Smith, T. J.; Strawn, J. R.; Trent, D.; Giaccone, G.; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 2009, 27, 6251-6266.
77. Laurent-Puig, P.; Taieb, J. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? Curr. Opin. Oncol. 2008, 20, 454-458.
78. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
79. Vogel, C. L.; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M.; Shak, S.; Stewart, S. J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20, 719-726.
80. Smith, I. E.; Walsh, G.; Skene, A.; Llombart, A.; Mayordomo, J. I.; Detre, S.; Salter, J.; Clark, E.; Magill, P.; Dowsett, M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 2007, 25, 3816-3822.
81. Ritter, C. A.; Perez-Torres, M.; Rinehart, C.; Guix, M.; Dugger, T.; Engelman, J. A.; Arteaga, C. L. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 2007, 13, 4909-4919.
82. Nagata, Y.; Lan, K.H.; Zhou, X.; Tan, M.; Esteva, F. J.; Sahin, A. A.; Klos, K. S.; Li, P.; Monia, B. P.; Nguyen, N. T.; Hortobagyi, G. N.; Hung, M. C.; Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6, 117-127.
83. Maehama, T. PTEN: its deregulation and tumorigenesis. Biol. Pharm. Bull. 2007, 30, 1624-1627.
84. Bose, S.; Crane, A.; Hibshoosh, H.; Mansukhani, M.; Sandweis, L.; Parsons, R. Reduced expression of PTEN correlates with breast cancer progression. Hum. Pathol. 2002, 33, 405-409.
85. LeRoith, D.; Roberts, C. T. Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003, 195, 127-137.
86. Nahta, R.; Yuan, L. X.; Zhang, B.; Kobayashi, R.; Esteva, F. J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65, 11118-11128.
87. Codony-Servat, J.; Albanell, J.; Lopez-Talavera, J. C.; Arribas, J.; Baselga, J. Cleavage of the HER2 ectodomain is a pervanadateactivable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 1999, 59, 1196-1201.
88. Anido, J.; Scaltriti, M.; Bech Serra, J. J.; Santiago Josefat, B.; Todo, F. R.; Baselga, J.; Arribas, J. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 2006, 25, 3234-3244.
89. Molina, M. A.; Sáez, R.; Ramsey, E. E.; Garcia-Barchino, M. J.; Rojo, F; Evans A. J.; Albanell, J.; Keenan, E. J.; Lluch, A.; García-Conde, J.; Baselga, J.; Clinton, G. M. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 2002, 8, 347-353.
90. Bedard, P. L.; Cardoso, F.; Piccart-Gebhart, M. J. Stemming resistance to HER-2 targeted therapy. J. Mamm. Gland Biol. Neoplasia 2009, 14, 55-66.
91. Pegram, M. D.; Reese, D. M. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin. Oncol. 2002, 29(Suppl. 11), 29-37.
92. Strome, S. E.; Sausville, E. A.; Mann, D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007, 12, 1084-1095.
93. Scaltriti, M.; Rojo, F.; Ocaña, A.; Anido, J.; Guzman, M.; Cortes, J.; Di Cosimo, S.; Matias-Guiu, X.; Ramony Cajal, S.; Arribas, J.; Baselga, J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 2007, 99, 628-638.
94. Berns, K.; Horlings, H. M.; Hennessy, B. T.; Madiredjo, M.; Hijmans, E. M.; Beelen, K.; Linn, S. C.; Gonzalez-Angulo, A. M.; Stemke-Hale, K.; Hauptmann, M.; Beijersbergen, R. L.; Mills, G. B.; van de Vijver, M. J.; Bernards, R. A. Functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12, 395-402.
95. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennini, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652-6659.
96. Chu, I.; Blackwell, K.; Chen, S.; Slingerland, J. The dual ErbB1/HER2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005, 65, 18-25.
97. Konecny, G. E.; Pegram, M. D.; Venkatesan, N.; Finn, R.; Yang, G.; Rahmeh, M.; Untch, M.; Rusnak, D. W.; Speha, R.G.; Mullin, R.J.; Keith, B. R.; Gilmer, T. M.; Berger, M.; Podratz, K. C.; Slamon, D. J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66, 1630-1639.
98. Zhou, H.; Kim, Y. S.; Peletier, A.; McCall, W.; Earp, H. S.; Sartor, C. I. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 344-352.
99. Amir, E.; Ocaña, A.; Seruga, B.; Freedman, O.; Clemons, M. Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treat. Rev. 2010, Jan 23.[Epub ahead of print].
100. Nahta, R.; Yuan, L. X.; Du, Y.; Esteva, F. J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol. Cancer Ther. 2007, 6, 667-674.
101. Scaltriti, M.; Verma, C.; Guzman, M.; Jimenez, J.; Parra, J. L.; Pedersen, K.; Smith, D. J.; Landolfi, S.; Ramony Cajal, S.; Arribas, J.; Baselga, J. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009, 28, 803-814.
102. Wainberg, Z. A.; Anghel, A.; Desai, A. J.; Ayala, R.; Luo, T.; Safran, B.; Fejzo, M. S.; Hecht, J. R.; Slamon, D. J.; Finn, R. S. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 2010, 16, 1509-1519.
103. Jørgensen, J. T. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010, 78, 26-33.
104. Geyer, C. E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C. G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S. D.; Stein, S.; Cameron, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355, 2733-2743.
105. Johnston, S.; Pippen, J. Jr.; Pivot, X.; Lichinitser, M.; Sadeghi, S.; Dieras, V.; Gomez, H. L.; Romieu, G.; Manikhas, A.; Kennedy, M. J.; Press, M. F.; Maltzman, J.; Florance, A.; O'Rourke, L.; Oliva, C.; Stein, S.; Pegram, M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27, 5538-5546.
106. Minkovsky, N.; Berezov, A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs 2008, 9, 1336-1346.
107. Schütze, C.; Dörfler, A.; Eicheler, W.; Zips, D.; Hering, S.; Solca, F.; Baumann, M.; Krause, M. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol. 2007, 183, 256-264.
108. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27, 4702-4711.
109. Eskens, F. A.; Mom, C. H.; Planting, A. S.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 2008, 98, 80-85.
110. Allen, L. F.; Eiseman, I. A.; Fry, D. W.; Lenehan, P. F. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin. Oncol. 2003, 30(Suppl 16), 65-78.
111. Slichenmyer, W. J.; Elliott, W. L.; Fry, D. W. CI-1033, a pan-erbB tyrosine kinas inhibitor. Semin. Oncol. 2001, 29, 80-85.
112. Allen, L. F.; Lenehan, P. F.; Eiseman, I. A.; Elliott, W. L.; Fry, D. W. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin. Oncol. 2002, 29, 11-21.
113. Rao, G. S.; Murray, S.; Ethier, S. P. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 1519-1528.
114. Gieseg, M. A.; de Bock, C.; Ferguson, L. R.; Denny, W. A. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001, 12, 683-690.
115. Erlichman, C.; Boerner, S. A.; Hallgren, C. G.; Spieker, R.; Wang, X. Y.; James C. D.; Scheffer, G. L.; Maliepaard, M.; Ross, D. D.; Bible, K. C.; Kaufmann, S. H. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance proteinmediated drug efflux. Cancer Res. 2001, 61, 739-748.
116. Jänne, P. A.; von Pawel, J.; Cohen, R. B.; Crino, L.; Butts, C. A.; Olson, S. S.; Eiseman, I. A.; Chiappori, A. A.; Yeap, B. Y.; Lenehan, P. F.; Dasse, K.; Sheeran, M.; Bonomi, P. D. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 3936-3944.
117. Rixe, O.; Franco, S. X.; Yardley, D. A.; Johnston, S. R.; Martin, M.; Arun, B. K.; Letrent, S. P.; Rugo, H. S. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother. Pharmacol. 2009, 64, 1139-1148.
118. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Greenberger, L. M.; Tsou, H. R. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of orally active irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 2003, 46, 49-63.
119. Burstein, H. J.; Sun, Y.; Dirix, L. Y.; Jiang, Z.; Paridaens, R.; Tan, A. R.; Awada, A.; Ranade, A.; Jiao, S.; Schwartz, G.; Abbas, R.; Powell, C.; Turnbull, K.; Vermette, J.; Zacharchuk, C.; Badwe, R. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 2010, 28, 1301-1307.
120. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.; Wissner, A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004, 64, 3958-3965.
121. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 2005, 102, 7665-7670.
122. Wong, K. K.; Fracasso, P. M.; Bukowski, R. M.; Lynch, T. J.; Munster, P. N.; Shapiro, G. I.; Jänne, P. A.; Eder, J. P.; Naughton, M. J.; Ellis, M. J.; Jones, S. F.; Mekhail, T.; Zacharchuk, C.; Vermette, J.; Abbas, R.; Quinn, S.; Powell, C.; Burris, H. A. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res. 2009, 15, 2552-2558.
123. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Kinzler, K. W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P.; Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000, 6, 1024-1028.
124. Nunes, M.; Shi, C.; Greenberger, L. M. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol. Cancer Ther. 2004, 3, 21-27.
125. Erlichman, C.; Hidalgo, M.; Boni, J. P.; Martins, P.; Quinn, S. E.; Zacharchuk, C.; Amorusi, P.; Adjei, A. A.; Rowinsky, E. K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 2006, 24, 2252-2260.
126. Laheru, D.; Croghan, G.; Bukowski, R.; Rudek, M.; Messersmith, W.; Erlichman, C.; Pelley, R.; Jimeno, A.; Donehower, R; Boni, J.; Abbas, R.; Martins, P.; Zacharchuk, C.; Hidalgo, M. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin. Cancer Res. 2008, 14, 5602-5609.
127. Ocaña, A.; Amir, E. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat. Rev. 2009, 35, 685-691.
128. Costa, L. J.; Drabkin, H. A. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007, 12, 1404-1415.
129. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932-936.
130. Ribatti, D.; Vacca, A. The role of microenvironment in tumor angiogenesis. Genes Nutr. 2008, 3, 29-34.
131. Ribatti, D. Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis 2008, 11, 3-10.
132. Verheul, H. M.; Voest, E. E.; Schlingemann, R. O. Are tumours angiogenesis-dependent? J. Pathol. 2004, 202, 5-13.
133. Zhong, H.; Bowen, J. P. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr. Med. Chem. 2006, 13, 849-862.
134. Ferrara, N.; Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 2005, 438, 967-974.
135. Vincenti, V.; Cassano, C.; Rocchi, M.; Persico, G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996, 93, 1493-1495.
136. Houck, K. A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 1991, 5, 1806-1814.
137. Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J. C.; Abraham, J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 1991, 266, 11947-11954.
138. Kaelin, W. G. Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009, 115, 2262-2272.
139. Cohen, T.; Nahari, D.; Cerem, L. W.; Neufeld, G.; Levi, B. Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 1996, 271, 736-741.
140. Claffey, K. P.; Abrams, K.; Shih, S. C.; Brown, L. F.; Mullen, A.; Keough, M. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab. Invest. 2001, 81, 61-75.
141. Pal, S.; Datta, K.; Mukhopadhyay, D. Central role of p53 on regulation of vascular permeabilità factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 2001, 61, 6952-6957.
142. Applanat, M. P.; Buteau-Lozano, H.; Herve, M. A.; Corpet, A. Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv. Exp. Med. Biol. 2008, 617, 437-444.
143. Ferrara, N.; Gerber, H. P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669-676.
144. Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7, 359-371.
145. Tammela, T.; Enholm, B.; Alitalo, K.; Paavonen, K. The biology of vascular endothelial growth factors. Cardiovasc. Res. 2005, 65, 550-563.
146. Tabernero, J. The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 2007, 5, 203-220.
147. Gordon, M. S.; Mendelson, D. S.; Kato, G. Tumor angiogenesis and novel antiangiogenic strategies. Int. J. Cancer 2010, 126, 1777-1787.
148. Gotink, K. J.; Verheul, H. M. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010, 13, 1-14.
149. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9, 327-337.
150. Kim, D. W.; Jo, Y. S.; Jung, H. S.; Chung, H. K.; Song, J. H.; Park, K. C.; Park, S. H.; Hwang, J. H.; Rha, S. Y.; Kweon, G. R.; Lee, S. J.; Jo, K. W.; Shong, M. An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 2006, 91, 4070-4076.
151. Arora, A.; Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005, 315, 971-979.
152. Potapova, O.; Laird, A. D.; Nannini, M. A.; Barone, A.; Li, G.; Moss, K. G.; Cherrington, J. M.; Mendel, D. B. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol. Cancer Ther. 2006, 5, 1280-1289.
153. Laird, A. D.; Cherrington, J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs 2003, 12, 51-64.
154. Osusky, K. L; Hallahan, D. E; Fu, A.; Ye, F.; Shyr, Y.; Geng, L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004, 7, 225-233.
155. Heinrich, M. C.; Blanke, C. D.; Druker, B. J.; Corless, C. L. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002, 20, 1692-1703.
156. Houk, B. E.; Bello, C. L.; Kang, D.; Amantea, M. A. population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 2009, 15, 2497-2506.
157. Kulke, M. H.; Lenz, H. J.; Meropol, N. J.; Posey, J.; Ryan, D. P.; Picus, J.; Bergsland, E.; Stuart, K.; Tye, L.; Huang, X.; Li, J. Z.; Baum, C. M.; Fuchs, C. S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2008, 26, 3403-3410.
158. Burstein, H. J.; Elias, A. D.; Rugo, H. S.; Cobleigh, M. A.; Wolff, A. C.; Eisenberg, P. D.; Lehman, M.; Adams, B. J.; Bello, C. L.; De Primo, S. E.; Baum, C. M.; Miller, K. D. A phase II study of sunitinib malate, an oral multitargeted tyrosine tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26, 1810-1816.
159. Motzer, R. J.; Rini, B. I.; Bukowski, R. M.; Curti, B. D.; George, D. J.; Hudes, G. R.; Redman, B. G.; Margolin, K. A.; Merchan, J. R.; Wilding, G.; Ginsberg, M. S.; Bacik, J.; Kim, S. T.; Baum, C. M.; Michaelson, M. D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295, 2516-2524.
160. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S. T.; Chen, I.; Bycott, P. W.; Baum, C. M.; Figlin, R. A. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 115-124.
161. Demetri, G. D.; van Oosterom, A. T.; Garrett, C. R.; Blackstein, M. E.; Shah, M. H.; Verweij, J.; McArthur, G.; Judson, I. R.; Heinrich, M. C.; Morgan, J. A.; Desai, J.; Fletcher, C. D.; George, S.; Bello, C. L.; Huang, X.; Baum, C. M.; Casali, P. G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368, 1329-1338.
162. Blay, J. Y. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann. Oncol. 2010, 21, 208-215.
163. Gnarra, J. R; Tory, K.; Weng, Y.; Schmidt, L.; Wei, M. H.; Li, H.; Latif, F.; Liu, S.; Chen, F.; Duh, F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 1994, 7, 85-90.
164. Linehan, W. M.; Lerman, M. I.; Zbar, B. Identification of the VHL gene: its role in renal carcinoma. JAMA 1995, 273, 564-570.
165. Kondo, K.; Kico, J.; Nakamura, E.; Lechpammer, M.; Kaelin, W. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1, 237-246.
166. Choueiri, T. K.; Schutz, F. A.; Je, Y.; Rosenberg, J. E.; Bellmunt, J. Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. J. Clin. Oncol. 2010, Mar 29[Epub ahead of print].
167. Heinrich, M. C.; Corless, C. L.; Duensing, A.; McGreevey, L.; Chen, C. J.; Joseph, N.; Singer, S.; Griffith, D. J.; Haley, A.; Town, A.; Demetri, G. D.; Fletcher, C. D.; Fletcher, J. A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299, 708-710.
168. Corless, C. L.; Schroeder, A.; Griffith, D.; Town, A.; McGreevey, L.; Harrell, P.; Shiraga, S.; Bainbridge, T.; Morich, J.; Heinrich, M. C. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 2005, 23, 5357-5364.
169. Agaram, N. P.; Wong, G. C.; Guo, T.; Maki, R. G.; Singer, S.; De Matteo, R. P.; Besmer, P.; Antonescu, C. R. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008, 47, 853-859.
170. Tarn, C.; Rink, L.; Merkel, E.; Flieder, D.; Pathak, H.; Koumbi, D.; Testa, J. R.; Eisenberg, B.; von Mehren, M.; Godwin, A. K. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc. Natl. Acad. Sci. USA 2008, 105, 8387-8392.
171. Rutkowski, P.; Nowecki, Z. I.; Biec-Rychter, M. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J. Cancer Res. Clin. Oncol. 2007, 133, 589-597.
172. Gold, J. S.; van der Zwan, S. M.; Gönen, M.; Maki, R. G.; Singer, S.; Brennan, M. F.; Antonescu, C. R.; De Matteo, R. P. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann. Surg. Oncol. 2007, 14, 134-142.
173. Richter, K. K.; Schmid, C.; Thompson-Fawcett, M.; Settmacher, U.; Altendorf-Hofmann, A. Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours. Langenbecks Arch. Surg. 2008, 393, 949-955.
174. Dirnhofer, S.; Leyvraz, S. Current standards and progress in understanding and treatment of GIST. Swiss Med. Wkly. 2009, 139, 90-102.
175. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
176. Sridhar, S. S.; Hedley, D.; Siu, L. L. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 2005, 4, 677-685.
177. Carlomagno, F.; Anaganti, S.; Guida, T.; Salvatore, G.; Troncone, G.; Wilhelm, S. M.; Santoro, M. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 2006, 98, 326-334.
178. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. 2006, 5, 835-844.
179. Clark, J. W.; Eder, J. P.; Ryan, D.; Lathia, C.; Lenz, H. J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 2005, 11, 5472-5480.
180. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 125-134.
181. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Staehler, M.; Negrier, S.; Chevreau, C.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Anderson, S.; Hofilena, G.; Shan, M.; Pena, C.; Lathia, C.; Bukowski, R. M. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 2009, 27, 3312-3318.
182. Escudier, B.; Szczylik, C.; Hutson, T. E.; Demkow, T.; Staehler, M.; Rolland, F.; Negrier, S.; Laferriere, N.; Scheuring, U. J.; Cella, D.; Shah, S.; Bukowski, R. M. Randomized phase II trial of firstline treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27, 1280-1289.
183. Semela, D.; Dufour, J. F. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 2004, 41, 864-880.
184. Wiesenauer, C. A.; Yip-Schneider, M. T.; Wang, Y.; Schmidt, C. M. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J. Am. Coll. Surg. 2004, 198, 410-421.
185. Giambartolomei, S.; Covone, F.; Levrero, M.; Balsano, C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C Virus (HCV) core protein. Oncogene 2001, 20, 2606-2610.
186. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Wu, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Tsujinoue, H.; Masaki, T.; Fukui, H. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004, 39, 1517-1524.
187. Sennino, B.; Kuhnert, F.; Tabruyn, S. P.; Mancuso, M. R.; Hu-Lowe, D. D.; Kuo, C. J.; McDonald, D. M. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res. 2009, 69, 4527-4536.
188. Zhang, T.; Sun, H. C.; Xu, Y.; Zhang K. Z.; Wang, L.; Qin, L. X.; Wu, W. Z.; Liu, Y. K.; Ye, S. L.; Tang, Z. Y. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin. Cancer Res. 2005, 11, 8557-8563.
189. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66, 11851-11858.
190. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390.
191. Zhang, T.; Ding, X.; Wei, D.; Cheng, P.; Su, X.; Liu, H.; Wang, D.; Gao, H. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 2010, 21, 326-332.
192. Peck-Radosavljevic, M.; Greten T. F.; Lammer, J.; Rosmorduc, O.; Sangro, B.; Santoro, A.; Bolondi, L. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2010, 22, 391-398.
193. Kelly, R. J.; Rixe, O. Axitinib (AG-013736). Recent Results Cancer Res. 2010, 184, 33-44.
194. Solowiej, J.; Bergqvist, S.; McTigue, M. A.; Marrone, T.; Quenzer, T.; Cobbs, M.; Ryan, K.; Kania, R. S.; Diehl, W.; Murray, B. W. Characterizing the Effects of the Juxtamembrane Domain on Vascular Endothelial Growth Factor Receptor-2 Enzymatic Activity, Autophosphorylation, and Inhibition by Axitinib. Biochemistry 2009, 48, 7019-7031.
195. Wilmes, L. J.; Pallavicini, M. G.; Fleming, L. M.; Gibbs, J.; Wang, D.; Li, K. L.; Partridge, S. C.; Henry, R. G.; Shalinsky, D. R.; Hu-Lowe, D.; Park, J. W.; McShane, T. M.; Lu, Y.; Brasch, R. C.; Hylton, N. M. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 2007, 25, 319-327.
196. Rini, B. I.; Wilding, G.; Hudes, G.; Stadler, W. M.; Kim, S.; Tarazi, J.; Rosbrook, B.; Trask, P. C.; Wood, L.; Dutcher, J. P. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27, 4462-4468.
197. Sharma, S.; Abhyankar, V.; Burgess, R. E.; Infante, J.; Trowbridge, R. C.; Tarazi, J.; Kim, S.; Tortorici, M.; Chen, Y.; Robles, R. L. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann. Oncol. 2010, 21, 297-304.
198. Cohen, E. E.; Rosen, L. S.; Vokes, E. E.; Kies, M. S.; Forastiere, A. A.; Worden, F. P.; Kane, M. A.; Sherman, E.; Kim, S.; Bycott, P.; Tortorici, M.; Shalinsky, D. R.; Liau, K. F.; Cohen, R. B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J. Clin. Oncol. 2008, 26, 4708-4713.
199. Schiller, J. H.; Larson, T.; Ou, S. H.; Limentani, S.; Sandler, A.; Vokes, E.; Kim, S.; Liau, K.; Bycott, P.; Olszanski, A. J.; von Pawel, J. Efficacy and Safety of Axitinib in Patients with Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study. J. Clin. Oncol. 2009, 27, 3836-3841.
200. Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.; Jürgensmeier, J. M.; Ogilvie, D. J. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005, 65, 4389-4400.
201. Takeda, M.; Arao, T.; Yokote, H.; Komatsu, T.; Yanagihara, K.; Sasaki, H.; Yamada, Y.; Tamura, T.; Fukuoka, K.; Kimura, H.; Saijo, N.; Nishio, K. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin. Cancer Res. 2007, 13, 3051-3057.
202. Kamoun, W. S.; Ley, C. D.; Farrar, C. T.; Duyverman, A. M.; Lahdenranta, J.; Lacorre, D. A.; Batchelor, T. T.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Fukumura, D.; Sorensen, A. G.; Jain, R. K. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 2009, 27, 2542-2552.
203. Sorensen, A. G.; Batchelor, T. T.; Zhang, W. T.; Chen, P. J.; Yeo, P.; Wang, M.; Jennings, D.; Wen, P. Y.; Lahdenranta, J.; Ancukiewicz, M.; di Tomaso, E.; Duda, D. G.; Jain, R. K. A vascular normalization index as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009, 69, 5296-5300.
204. Chen, E.; Jonker, D.; Gauthier, I.; MacLean, M.; Wells, J.; Powers, J.; Seymour, L. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Clin. Cancer Res. 2009, 15, 1481-1486.
205. Goss, G. D.; Arnold, A.; Shepherd, F. A.; Dediu, M.; Ciuleanu, T. E.; Fenton, D.; Zukin, M.; Walde, D.; Laberge, F.; Vincent, M. D.; Ellis, P. M.; Laurie, S. A.; Ding, K.; Frymire, E.; Gauthier, I.; Leighl, N. B.; Ho, C.; Noble, J.; Lee, C. W.; Seymour, L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J. Clin. Oncol. 2010, 28, 49-55.
206. van Cruijsen, H.; Voest, E. E.; Punt, C. J.; Hoekman, K.; Witteveen, P. O.; Meijerink, M. R.; Puchalski, T. A.; Robertson, J.; Saunders, O.; Jürgensmeier, J. M.; van Herpen, C. M.; Giaccone, G. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur. J. Cancer 2010, 46, 901-911.
207. Fiedler, W.; Mesters, R.; Heuser, M.; Ehninger, G.; Berdel, W. E.; Zirrgiebel, U.; Robertson, J. D.; Puchalski, T. A.; Collins, B.; Jürgensmeier, J. M.; Serve, H. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk. Res. 2010, 34, 196-202.
208. Langenberg, M. H.; van Herpen, C. M.; De Bono, J.; Schellens, J. H.; Unger, C.; Hoekman, K.; Blum, H. E.; Fiedler, W.; Drevs, J.; Le Maulf, F.; Fielding, A.; Robertson, J.; Voest, E. E. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J. Clin. Oncol. 2009, 27, 6152-6159.
209. Matulonis, U. A.; Berlin, S.; Ivy, P.; Tyburski, K.; Krasner, C.; Zarwan, C.; Berkenblit, A.; Campos, S.; Horowitz, N.; Cannistra, S. A.; Lee, H.; Lee, J.; Roche, M.; Hill, M.; Whalen, C.; Sullivan, L.; Tran, C.; Humphreys, B. D.; Penson, R. T. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol. 2009, 27, 5601-5606.
210. Robertson, J. D.; Botwood, N. A.; Rothenberg, M. L.; Schmoll, H. J. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin. Colorectal Cancer 2009, 8, 59-60.
211. Sonpavde, G.; Hutson, T. E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep. 2007, 9, 115-119.
212. Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-Ward, R. G.; Epperly, A. H.; Hinkle, K. W.; Hunter, R. N. 3rd; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 2008, 51, 4632-4640.
213. Kumar, R.; Knick, V. B.; Rudolph, S. K.; Johnson, J. H.; Crosby, R. M.; Crouthamel, M. C.; Hopper, T. M.; Miller, C. G.; Harrington, L. E.; Onori, J. A.; Mullin, R. J.; Gilmer, T. M.; Truesdale, A. T.; Epperly, A. H.; Boloor, A.; Stafford, J. A.; Luttrell, D. K.; Cheung, M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 2007, 6, 2012-2021.
214. Sternberg, C. N.; Davis, I. D.; Mardiak, J.; Szczylik, C.; Lee, E.; Wagstaff, J.; Barrios, C. H.; Salman, P.; Gladkov, O. A.; Kavina, A.; Zarbá, J. J.; Chen, M.; McCann, L.; Pandite, L.; Roychowdhury, D. F.; Hawkins, R. E. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010, 28, 1061-1088.
215. Iwamoto, F. M.; Lamborn, K. R.; Robins, H. I.; Mehta, M. P.; Chang, S. M.; Butowski, N. A.; Deangelis, L. M.; Abrey, L. E.; Zhang, W. T.; Prados, M. D.; Fine, H. A. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010, Mar 3[Epub ahead of print].
216. Kim, K.; Ryu, S. Y. Major clinical research advances in gynecologic cancer 2009. J. Gynecol. Oncol. 2009, 20, 203-209.
217. Sleijfer, S.; Ray-Coquard, I.; Papai, Z.; Le Cesne, A.; Scurr, M.; Schöffski, P.; Collin, F.; Pandite, L.; Marreaud, S.; De Brauwer, A.; van Glabbeke, M.; Verweij, J.; Blay, J. Y. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol. 2009, 27, 3126-3132.
218. Bukowski, R. M.; Yasothan, U.; Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov. 2010, 9, 17-18.
219. Hennequin, L. F.; Stokes, E. S.; Thomas, A. P.; Johnstone, C.; Plé, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
220. Carlomagno, F.; Vitagliano, D.; Guida, T.; Ciardiello, F.; Tortora, G.; Vecchio, G.; Ryan, A. J.; Fontanini, G.; Fusco, A.; Santoro, M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002, 62, 7284-7290.
221. Runeberg-Roos, P.; Saarma, M. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann. Med. 2007, 39, 572-580.
222. Santarpia, L.; Ye, L.; Gagel, R. F. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J. Intern. Med. 2009, 266, 99-113.
223. Drosten, M.; Pützer, B. M. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat. Clin. Pract. Oncol. 2006, 3, 564-574.
224. Croyle, M.; Akeno, N.; Knauf, J. A.; Fabbro, D.; Chen, X.; Baumgartner, J. E.; Lane, H. A.; Fagin, J. A. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 2008, 68, 4183-4191.
225. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
226. Morabito, A.; Piccirillo, M. C.; Falasconi, F.; De Feo, G.; Del Giudice, A.; Bryce, J.; Di Maio, M.; De Maio, E.; Normanno, N.; Perrone, F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009, 14, 378-390.
227. Tamura, T.; Minami, H.; Yamada, Y.; Yamamoto, N.; Shimoyama, T.; Murakami, H.; Horiike, A.; Fujisaka, Y.; Shinkai, T.; Tahara, M.; Kawada, K.; Ebi, H.; Sasaki, Y.; Jiang, H.; Saijo, N. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J. Thorac. Oncol. 2006, 9, 1002-1009.
228. Robinson, B. G.; Paz-Ares, L.; Krebs, A.; Vasselli, J.; Haddad, R. Vandetanib (100 Milligrams) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. J. Clin. Endocrinol. Metab. 2010, Apr 6.[Epub ahead of print].
229. Wells, S. A. Jr.; Gosnell, J. E.; Gagel, R. F.; Moley, J.; Pfister, D.; Sosa, J. A.; Skinner, M.; Krebs, A.; Vasselli, J.; Schlumberger, M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 2010, 28, 767-772.
230. Traxler, P.; Allegroni, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004, 64, 4931-4941.
231. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132.
232. Drevs, J.; Müller-Driver, R.; Wittig, C.; Fuxius, S.; Esser, N; Hugenschmidt, H.; Konerding, M. A.; Allegrini, P. R.; Wood, J.; Hennig, J.; Unger, C.; Marmé D. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002, 62, 4015-4122.
233. Banerjee, S.; Zvelebil, M.; Furet, P.; Mueller-Vieira, U.; Evans, D. B.; Dowsett, M.; Martin, L. A. The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. Cancer Res. 2009, 69, 4716-4723.
234. Thomas, A. L.; Morgan, B.; Horsfield, M. A.; Higginson, A.; Kay, A.; Lee, L.; Masson, E.; Puccio-Pick, M.; Laurent, D.; Steward, W. P. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 4162-4171.
235. Los, M.; Roodhart, J. M.; Voest, E. E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007, 12, 443-450.
236. Wagner, A. D.; Arnold, D.; Grothey, A. A.; Haerting, J.; Unverzagt, S. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst. Rev. 2009, 3, CD005392.
237. Chang, Y. M.; Kung, H. J.; Evans, C. P. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007, 9, 90-100.
238. Neet, K.; Hunter, T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1996, 1, 147-169.
239. Krause, D. S.; Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353, 172-187.
240. Druker, B. J.; Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 2000, 105, 3-7.
241. Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243, 290-293.
242. Melo, J. V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996, 88, 2375-2384.
243. Lugo, T. G.; Pendergast, A. M.; Muller, A. J.; Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247, 1079-1082.
244. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2, 561-566.
245. Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M. W.; Silver, R. T.; Goldman, J. M.; Stone, R. M.; Cervantes, F.; Hochhaus, A.; Powell, B. L.; Gabrilove, J. L.; Rousselot, P.; Reiffers, J.; Cornelissen, J. J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J. L.; Radich, J. P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R. A.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355, 2408-2417.
246. Cortes, J. E.; Baccarani, M.; Guilhot, F.; Druker, B. J.; Branford, S.; Kim, D. W.; Pane, F.; Pasquini, R.; Goldberg, S. L.; Kalaycio, M.; Moiraghi, B.; Rowe, J. M.; Tothova, E.; De Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H. M.; Radich, J. P.; Hughes, T. P. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 2010, 28, 424-430.
247. Kharas, M. G.; Deane, J. A.; Wong, S.; Kharas, M. G.; Deane, J. A.; Wong, S.; O'Bosky, K. R.; Rosenberg, N.; Witte, O. N.; Fruman, D. A. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 2004, 103, 4268-4275.
248. Jain, S. K.; Susa, M.; Keeler, M. L.; Carlesso, N.; Druker, B.; Varticovski, L. PI 3-kinase activation in BCR/abl transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl. Blood 1996, 88, 1542-1550.
249. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96, 857-868.
250. Frank, D. A.; Varticovski, L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996, 10, 1724-1730.
251. Gesbert, F.; Griffin, J. D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000, 96, 2269-2276.
252. Magné, S.; Caron, S.; Charon, M.; Rouyez, M. C.; Dusanter-Fourt, I. STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol. Cell Biol. 2003, 23, 8934-8945.
253. Bewry, N. N.; Nair, R. R.; Emmons, M. F.; Boulware, D.; Pinilla-Ibarz, J.; Hazlehurst, L. A. Stat3 contributes to resistance towards BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol. Cancer Ther. 2008, 7, 3169-3175.
254. Cortez, D.; Reuther, G.; Pendergast, A. M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1- to-S phase transition in hematopoietic cells. Oncogene 1997, 15, 2333-2342.
255. Andreu, E. J.; Lledó, E.; Poch, E.; Ivorra, C.; Albero, M. P.; Martínez-Climent, J. A.; Montiel-Duarte, C.; Rifón, J.; Pérez-Calvo, J.; Arbona, C.; Prósper, F.; Pérez-Roger, I. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 2005, 65, 3264-3272.
256. Hochhaus, A.; O'Brien, S. G.; Guilhot, F.; Druker, B. J.; Branford, S.; Foroni, L.; Goldman, J. M.; Müller, M. C.; Radich, J. P.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T. P.; Larson, R. A.; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23, 1054-1061.
257. Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R. T.; Goldman, J.; Hehlmann, R.; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 2009, 27, 6041-6051.
258. Larson, R. A.; Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Riviere, G. J.; Krahnke, T.; Gathmann, I.; Wang, Y.; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety inchronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111, 4022-4028.
259. Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R. T.; Goldman, J.; Hehlmann, R.; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 2009, 27, 6041-6051.
260. Apperley, J. F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8, 1018-1029.
261. O'Hare, T.; Eide, C. A.; Deininger, M. W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110, 2242-2249.
262. Sharma, P.; Mohanty, S.; Kochupillai, V.; Kumar, L. Mutations in ABL kinase domain are associated with inferior progression-free survival. Leuk. Lymphoma 2010, Apr 1.[Epub ahead of print].
263. Buchdunger, E.; Cioffi, C. L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B. J.; Lydon, N. B. Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000, 295, 139-145.
264. De Matteo, R. P.; Lewis, J. J.; Leung, D.; Mudan, S. S.; Woodruff, J. M.; Brennan, M. F. Two hundred gastrointestinal stromal tumors: recurrence pattern and prognostic factors for survival. Ann. Surg. 2000, 231, 51-58.
265. Verweij, J.; van Oosterom, A.; Blay, J. Y.; Judson, I.; Rodenhuis, S.; van der Graaf, W.; Radford, J.; Le Cesne, A.; Hogendoorn, P. C.; di Paola, E. D.; Brown, M.; Nielsen, O. S. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer 2003, 39, 2006-2011.
266. Heinrich, M. C.; Corless, C. L.; Blanke, C. D.; Demetri, G. D.; Joensuu, H.; Roberts, P. J.; Eisenberg, B. L.; von Mehren, M.; Fletcher, C. D.; Sandau, K.; McDougall, K.; Ou, W. B.; Chen, C. J.; Fletcher J. A. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 2006, 24, 4764-4774.
267. Debiec-Rychter, M.; Sciot, R.; Le Cesne, A.; Schlemmer, M.; Hohenberger, P.; van Oosterom, A. T.; Blay, J. Y.; Leyvraz, S.; Stul, M.; Casali, P. G.; Zalcberg, J.; Verweij, J.; Van Glabbeke, M.; Hagemeijer, A.; Judson, I.; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur. J. Cancer 2006, 42, 1093-1103.
268. Cassier, P. A.; Blay, J. Y. Molecular response prediction in gastrointestinal stromal tumors. Target Oncol. 2010, Apr 2.[Epub ahead of print].
269. Thomas, J.; Wang, L.; Clark, R. E.; Pirmohamed, M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104, 3739-3745.
270. Stamatakos, M.; Douzinas, E.; Stefanaki, C.; Safioleas, P.; Polyzou, E.; Levidou, G.; Safioleas, M. Gastrointestinal stromal tumor. World J. Surg. Oncol. 2009, 7, 61-70.
271. Cross, N. C.; Reiter, A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008, 119, 199-206.
272. David, M.; Cross, N. C.; Burgstaller, S.; Chase, A.; Curtis, C.; Dang, R.; Gardembas, M.; Goldman, J. M.; Grand, F.; Hughes, G.; Huguet, F.; Lavender, L.; McArthur, G. A.; Mahon, F. X.; Massimini, G.; Melo, J.; Rousselot, P.; Russell-Jones, R. J.; Seymour, J. F.; Smith, G.; Stark, A.; Waghorn, K.; Nikolova, Z.; Apperley, J. F. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007, 109, 61-64.
273. Baccarani, M.; Cilloni, D.; Rondoni, M.; Ottaviani, E.; Messa, F.; Merante, S.; Tiribelli, M.; Buccisano, F.; Testoni, N.; Gottardi, E.; de Vivo, A.; Giugliano, E.; Iacobucci, I.; Paolini, S.; Soverini, S.; Rosti, G.; Rancati, F.; Astolfi, C.; Pane, F.; Saglio, G.; Martinelli, G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR-alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92, 1173-1179.
274. Tefferi, A.; Gotlib, J.; Pardanani, A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin. Proc. 2010, 85, 158-164.
275. Jovanovic, J.V.; Score, J.; Waghorn, K.; Cilloni, D.; Gottardi, E.; Metzgeroth, G.; Erben, P.; Popp, H.; Walz, C.; Hochhaus, A.; Roche-Lestienne, C.; Preudhomme, C.; Solomon, E.; Apperley, J.; Rondoni, M.; Ottaviani, E.; Martinelli, G.; Brito-Babapulle, F.; Saglio, G.; Hehlmann, R.; Cross, N. C.; Reiter, A.; Grimwade, D. Low dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109, 4635-4640.
276. Lierman, E.; Folens, C.; Stover, E. H.; Mentens, N.; Van Miegroet, H.; Scheers, W.; Boogaerts, M.; Vandenberghe, P.; Marynen, P.; Cools, J. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108, 1374-1376.
277. Kalac, M.; Quintas-Cardama, A.; Vrhovac, R.; Kantarjian, H.; Verstovsek, S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 2007, 110, 955-964.
278. Bunimovich, O.; Grassi, M.; Baer, M. R. Systemic mastocytosis: classification, pathogenesis, diagnosis, and treatment. Cutis 2009, 83, 29-36.
279. Zermati, Y.; De Sepulveda, P.; Feger, F.; Letard, S.; Kersual, J.; Casteran, N.; Gorochov, G.; Dy, M.; Ribadeau Dumas, A.; Dorgham, K.; Parizot, C.; Bieche, Y.; Vidaud, M.; Lortholary, O.; Arock, M.; Hermine, O.; Dubreuil, P. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003, 22, 660-664.
280. Akin, C.; Brockow, K.; D'Ambrosio C.; Kirshenbaum, A. S.; Ma, Y.; Longley, B. J.; Metcalfe, D. D. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp. Hematol. 2003, 31, 686-692.
281. Orfao, A.; Garcia-Montero, A. C.; Sanchez, L.; Escribano L.; REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br. J. Haematol. 2007, 138, 12-30.
282. Pettigrew, H. D.; Teuber, S. S.; Kong, J. S.; Gershwin, M. E. Contemporary challenges in mastocytosis. Clin. Rev. Allergy Immunol. 2010, 38, 125-134.
283. Sirvent, N.; Maire, G.; Pedeutour, F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003, 37, 1-19.
284. Patel, K. U.; Szabo, S. S.; Hernandez, V. S.; Prieto, V. G.; Abruzzo, L. V.; Lazar, A. J.; López-Terrada, D. DermatoWbrosarcoma protuberans COL1A1-PDGFB fusion is identiWed in virtually all dermatoWbrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and Xuorescence in situ hybridization assays. Hum. Pathol. 2008, 39, 184-193.
285. Lemm, D.; Mügge, L. O.; Mentzel, T.; Höffken, K. Current treatment options in dermatofibrosarcoma protuberans. J. Cancer Res. Clin. Oncol. 2009, 135, 653-665.
286. Rutkowski, P.; Van Glabbeke, M.; Rankin, C. J.; Ruka, W.; Rubin, B. P.; Debiec-Rychter, M.; Lazar, A.; Gelderblom, H.; Sciot, R.; Lopez-Terrada, D.; Hohenberger, P.; van Oosterom, A. T.; Schuetze, S. M.; European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J. Clin. Oncol. 2010, 28, 1772-1779.
287. O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Jia, T.; Manley, P. W.; Mestan, J.; Cowan-Jacob, S. W.; Lee, F. Y.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005, 65, 4500-4505.
288. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N-(2-Chloro-6-methyl-phenyl)-2- (6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2 methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase Inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47, 6658-6661.
289. Wu, J.; Meng, F.; Lu, H.; Kong, L.; Bornmann, W.; Peng, Z.; Talpaz, M.; Donato, N. J. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinibresistant chronic myelogenous leukemia cells. Blood 2008, 111, 3821-3829.
290. Wu, J.; Meng, F.; Kong, L. Y.; Peng, Z.; Ying, Y.; Bornmann, W. G.; Darnay, B. G.; Lamothe, B.; Sun, H.; Talpaz, M.; Donato, N. J. Association between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase. J. Natl. Cancer Inst. 2008, 100, 926-939.
291. Boggon, T. J.; Eck, M. J. Structure and regulation of Src family kinases. Oncogene 2004, 23, 7918-7927.
292. Li, S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk. Lymphoma 2008, 49, 19-26.
293. Hochhaus, A.; Kantarjian, H. M.; Baccarani, M.; Lipton, J. H.; Apperley, J. F.; Druker, B. J.; Facon, T.; Goldberg, S. L.; Cervantes, F.; Niederwieser, D.; Silver, R. T.; Stone, R. M.; Hughes, T. P.; Muller, M. C.; Ezzeddine, R.; Countouriotis, A. M.; Shah, N. P. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109, 2303-2309.
294. Cortes, J.; Rousselot, P.; Kim, D. W.; Ritchie, E.; Hamerschlak, N.; Coutre, S.; Hochhaus, A.; Guilhot, F.; Saglio, G.; Apperley, J.; Ottmann, O.; Shah, N.; Erben, P.; Branford, S.; Agarwal, P.; Gollerkeri, A.; Baccarani, M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109, 3207-3213.
295. Haura, E. B.; Tanvetyanon, T.; Chiappori, A.; Williams, C.; Simon, G.; Antonia, S.; Gray, J.; Litschauer, S.; Tetteh, L.; Neuger, A.; Song, L.; Rawal, B.; Schell, M. J.; Bepler, G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 1387-1394.
296. Demetri, G. D.; Lo Russo, P.; MacPherson, I. R.; Wang, D.; Morgan, J. A.; Brunton, V. G.; Paliwal, P.; Agrawal, S.; Voi, M.; Evans, T. R. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15, 6232-6240.
297. Golemovic, M.; Verstovsek, S.; Giles, F.; Cortes, J.; Manshouri, T.; Manley, P. W.; Mestan, J.; Dugan, M.; Alland, L.; Griffin, J. D.; Arlinghaus, R. B.; Sun, T.; Kantarjian, H.; Beran, M. AMN107, a novel aminopyrimidine inhibitor of bcr-abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 2005, 11, 4941-4947.
298. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Brüggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl. Cancer Cell 2005, 7, 129-141.
299. Ray, A.; Cowan-Jacob, S. W.; Manley, P. W.; Mestan, J.; Griffin, J. D. Identification of BCR-ABL point mutations conferring resistance to the abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007, 109, 5011-5015.
300. Weisberg, E.; Manley, P.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. D. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 2006, 94, 1765-1769.
301. Kantarjian, H. M.; Giles, F.; Gattermann, N.; Bhalla, K.; Alimena, G.; Palandri, F.; Ossenkoppele, G. J.; Nicolini, F. E.; O'Brien, S. G.; Litzow, M.; Bhatia, R.; Cervantes, F.; Haque, A.; Shou, Y.; Resta, D. J.; Weitzman, A.; Hochhaus, A.; le Coutre, P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110, 3540-3546.
302. Breccia, M.; Alimena, G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk. Res. 2010, 34, 129-134.
303. Tanaka, C.; Yin, O. Q.; Sethuraman, V.; Smith, T.; Wang, X.; Grouss, K.; Kantarjian, H.; Giles, F.; Ottmann, O. G.; Galitz, L.; Schran, H. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin. Pharmacol. Ther. 2010, 87, 197-203.
304. Le Coutre, P.; Ottmann, O. G.; Giles, F.; Kim, D. W.; Cortes, J.; Gattermann, N.; Apperley, J. F.; Larson, R. A.; Abruzzese, E.; O'Brien, S. G.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F. X.; Saglio, G.; Gobbi, M.; Kwong, Y. L.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J. P.; Zheng, M.; Shou, Y.; Kantarjian, H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leucemia. Blood 2008, 111, 1834-1839.
305. Rosti, G.; Palandri, F.; Castagnetti, F.; Breccia, M.; Levato, L.; Gugliotta, G.; Capucci, A.; Cedrone, M.; Fava, C.; Intermesoli, T.; Cambrin, G. R.; Stagno, F.; Tiribelli, M.; Amabile, M.; Luatti, S.; Poerio, A.; Soverini, S.; Testoni, N.; Martinelli, G.; Alimena, G.; Pane, F.; Saglio, G.; Baccarani, M; GIMEMA CML Working Party. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009, 114, 4933-4938.
306. Dempke, W. C.; Heinemann, V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur. J. Cancer 2009, 45, 1117-1128.